Epidermal growth factor receptor (EGFR) and MEK inhibitors (EGFR/MEKi) are beneficial for the treatment of solid cancers but are frequently associated with severe therapylimiting acneiform skin toxicities. The underlying molecular mechanisms are poorly understood. Using gene expression profiling we identified IL-36γ and IL-8 as candidate drivers of EGFR/MEKi skin toxicity. We provide molecular and translational evidence that EGFR/MEKi in concert with the skin commensal bacterium Cutibacterium acnes act synergistically to induce IL-36γ in keratinocytes and subsequently IL-8, leading to cutaneous neutrophilia. IL-36γ expression was the combined result of C. acnes-induced NF-κB activation and EGFR/MEKi-mediated expression of the transcription factor Krüppel-like factor 4 (KLF4), due to the presence of both NF-κB-and KLF4-binding sites in the human IL-36γ gene promoter. EGFR/MEKi increased KLF4 expression by blockade of the EGFR-MEK-ERK pathway. These results provide an insight into understanding the pathological mechanism of the acneiform skin toxicities induced by EGFR/MEKi and identify IL-36γ and the transcription factor KLF4 as potential therapeutic targets.
Introduction
Agents targeting the epidermal growth factor receptor (EGFR)-mediated signaling pathway are increasingly used for the treatment of advanced lung, pancreatic, colorectal and head and neck cancers, which benefit from exacerbated EGFR activity for their growth and survival (1, 2) . Small molecule inhibitors of the Mitogen-activated protein kinases (MAPKs) signaling pathways including extracellular signal-regulated kinase (ERK) and MAPK/ERK kinase (MEK) 1 and 2 have also shown their efficacy in the treatment of various cancers, especially melanoma (3, 4) .
One significant clinical limitation to the prolonged use of EGFR and MEK inhibitors (EGFR/MEKi) is the occurrence of skin toxicities in 50-80% of patients, including an acneiform eruption that usually develops within the first few weeks of therapy (4) (5) (6) . The first monoclonal antibody and small molecule inhibitor of EGFR were approved by the FDA for the treatment of cancer twelve and thirteen years ago respectively, and since then skin toxicities induced by these drugs remain unsolved problems. Even though topical or oral agents alone or in combination are used to treat skin toxicities and show some efficacy, EGFR/MEKi-induced skin acneiform eruptions can still seriously affect patients' quality of life, leading physicians to reduce the dose administered or discontinue therapy in severe skin toxicity cases (7) (8) (9) . Importantly, the development and severity of the acneiform eruption have been shown to correlate with favorable anti-tumor responses (10) (11) (12) .
The exact molecular pathogenesis underlying the frequent and rapid development of skin toxicity to EGFR/MEKi is not understood to date. Animal studies using mice selectively lacking EGFR in the skin revealed that EGFR signaling is critical for normal skin barrier function and antimicrobial defense (13, 14) . However, the phenotype of mice selectively lacking EGFR in the skin resembles atopic dermatitis and is distinct from the acneiform skin toxicity seen in patients treated with EGFR/MEKi (15, 16) . In humans, histopathology of acneiform eruption lesions is characterized by folliculitis with massive infiltration of neutrophils histologically resembling acne vulgaris (5) . Another feature of acneiform toxicities caused by EGFR/MEKi and shared with acne vulgaris is the topographical predominance of inflammation in skin areas rich in pilosebaceous units, also corresponding to sebum-rich regions of the skin, such as the central face, upper chest, and back (17-21). These sebum-rich regions are highly colonized by Cutibacterium acnes (C. acnes, formerly known as Propionibacterium acnes) a lipophilic commensal representing the most abundant microorganism on the skin of healthy adults (19) (20) (21) (22) . While C. acnes is thought to play an important role in common acne, its involvement in EGFR/MEKi acneiform toxicities has never been investigated.
A better understanding of the molecular pathogenesis of acneiform eruption by EGFR/MEKi is still needed so as to guide the development of effective therapies to prevent or suppress the skin toxicity, while preserving their anti-tumor effects. Here, we investigate the molecular mechanisms of acneiform eruption associated with EGFR/MEKi.
Results

Skin gene expression profiling in EGFRi-induced acneiform skin toxicity
Employing an unbiased approach, we performed gene expression profiling of lesional skin biopsy samples from patients suffering from acneiform eruption by EGFRi ( Figure 1A and Supplemental Table 1 ). We found elevated IL-8 and IL-36γ in the patients' skin, whereas important inflammatory cytokines such as TNF-α, IL-6 and IL-17A were not significantly upregulated when compared to skin from healthy donors ( Figure 1A ). This observation was further confirmed by quantitative PCR with more lesional skin samples ( Figure 1B and Supplemental Figure 1A ). As previously reported, the expression of antimicrobial peptides such as RNase7 was also found to be decreased in patients' skin (14) (Supplemental Figure   1A ). IL-36γ is a proinflammatory cytokine of the IL-1 family, predominantly expressed by keratinocytes and is able to signal in an auto-or paracrine manner through the IL-36 receptor (also known as IL1RL2) and activates NF-κB signaling pathway in target cells. It has recently been shown that IL-36 plays a role in the cutaneous neutrophilic pustular autoinflammatory disease called DITRA (Deficiency of the IL-36 receptor antagonist) (23, 24) . Interestingly, IL-36γ has been demonstrated to induce prominent production of the potent neutrophil chemoattractant IL-8 (25) , which would be compatible with the extensive infiltration of neutrophils seen in skin lesions from patients suffering from acneiform eruptions (5) .
Furthermore, clinical trial data has shown that subcutaneous anti-IL-8 antibody injection strongly abrogates the induction of acneiform skin toxicity by EGFRi (26) . To define the cell types expressing IL-36γ in the skin of patients with acneiform eruption, immunohistochemical analyses and mRNA in situ hybridization were performed. In line with gene expression data, histochemical analysis of patients' lesions revealed elevated IL-36γ expression, which was predominantly localized in keratinocytes of epidermal hair follicles ( Figure 1C and Supplemental Figure 1B -C). This result and the fact that EGFR is preferentially expressed in undifferentiated and proliferating keratinocytes in the basal and suprabasal layers of the epidermis as well as the outer layers of the hair follicle (5) , led to the hypothesis that keratinocytes might be key players in the acneiform eruption by producing IL-36γ in response to EGFRi.
EGFRi and C. acnes synergize to promote IL-36γ expression and skin inflammation
To examine whether EGFR inhibition could lead to enhanced IL-36γ production in keratinocytes, primary human keratinocytes (PHKs) were exposed to the EGFRi erlotinib in vitro. Upon exposure to 1 μM erlotinib -a concentration compatible with the serum concentration found in treated patients (27) -PHKs produced 3.2-fold (p=0.048) higher levels of IL-36γ than upon exposure to vehicle alone as quantified by RT-PCR ( Figure 1D ). Given that both common acne vulgaris and EGFRi-induced eruptions occur in sebum-rich regions of the body that are colonized with C. acnes, and that C. acnes is known to be involved in the pathogenesis of acne (19-22), we exposed PHKs to both erlotinib and C. acnes. Interestingly, IL-36γ production at the mRNA and protein level was further enhanced (8.4-fold in mRNA, p=0.001) when PHKs were simultaneously exposed to erlotinib and C. acnes ( Figure 1D -E).
In contrast, the transcripts of other inflammatory cytokines such as TNF-α, IL-1β and IL-6
were not significantly increased by simultaneous exposure to erlotinib and C. acnes ( Figure   1D ). Similar levels of IL-36γ induction in PHKs were also observed with cetuximab, another EGFRi, when used in combination with C. acnes (Supplemental Figure 1D ). Furthermore, these results were confirmed when EGFR was genetically silenced using siRNA (Supplemental Figure 1E ).
Besides IL-36γ, expression of other genes were significantly increased in acneiform lesions by EGFRi, including the S100 proteins S100A12 and S100A8, the chemokine CXCL6 and the pleiotropic immunomodulatory cytokine IL-24 ( Figure 1A ). The regulation of the expression of these genes by erlotinib and C. acnes was also assessed in PHKs, and with the exception of S100A8, the expression of these genes was not as elevated as that of IL-36γ (Supplemental Figure 1F ). However, the expression of the above transcripts could be significantly induced in PHKs by exposure for 6 hours to IL-36γ alone (Supplemental Figure   1G ), suggesting that IL-36γ may be an upstream driver cytokine in EGFRi-induced acneiform eruption.
Similar to exposure to the TLR2 agonist C. acnes (28) (29) (30) , IL-36γ release into the culture supernatant of PHKs could be induced by exposure to erlotinib and the TLR2 agonist Pam3CSK4 ( Figure 1F ). In line with this, knocking down TLR2 attenuated IL-36γ production induced by erlotinib and C. acnes (Supplemental Figure 1H -I). Expression of the neutrophil chemoattractant IL-8 has previously been shown to be induced by IL-36γ (23, 25, (31) (32) (33) (34) (35) and was also found by gene expression profiling and quantitative PCR to be upregulated (32-fold, p=0 .041) in acneiform lesional skin ( Figure 1B ). To determine if simultaneous EGFR inhibition and TLR2 signaling can trigger IL-36γ-dependent production of IL-8 in human skin, we exposed normal human skin ex vivo to erlotinib and Pam3CSK4. In line with the neutrophil-rich inflammation and enhanced IL-8 gene expression observed in acneiform lesional skin by EGFRi, increased IL-8 production (16-fold, p=0.0051) was observed in human skin explants exposed to erlotinib and Pam3CSK4 as compared to vehicle, erlotinib or Pam3CSK4 alone ( Figure 1G ). In the same ex vivo experimental setting, addition of the recombinant IL-36 receptor antagonist to erlotinib and Pam3CSK4 resulted in a significant reduction of IL-8 production (4.1-fold, p=0.014) ( Figure 1G ), thus establishing the IL-36 dependency of IL-8 expression in human skin exposed simultaneously to EGFRi and TLR2 agonists. These data demonstrate that EGFR inhibition and simultaneous TLR2 activation act synergistically to drive keratinocyte IL-36γ expression with subsequent production of the neutrophil chemoattractant IL-8 in the skin. Taken together with the observed high levels of expression of IL-36γ and the neutrophil-rich inflammation observed in the pilo-sebaceous units of inflamed skin by EGFRi, this is suggestive of a central pathogenic role of keratinocyte-derived IL-36γ in the acneiform skin toxicity caused by EGFRi.
Increased expression and binding of the transcription factor KLF4 to the IL-36γ promoter upon EGFR inhibition
To understand how EGFRi and TLR2 signaling synergistically promote IL-36γ production in PHKs, we analyzed the transcriptional regulation of human IL-36γ. Histone modification patterns in PHKs revealed one enhancer and one promoter region upstream of the IL-36γ gene, the promoter region containing a binding site for the NF-κB subunit p65 (36) (Supplemental Figure 2A ). Interestingly, EGFR inhibition alone, or C. acnes exposure alone, resulted in only moderate enhancement of IL-36γ reporter activity as assessed in a Luciferase reporter assay of human IL-36γ transcriptional activity in PHKs (Figure 2A ). This is suggestive of the existence of two distinct responsive sites in the promoter region of the IL-36γ gene. In response to EGFR inhibition and C. acnes exposure, the activation pattern of a reporter containing both the IL-36γ enhancer and promoter regions was similar to the pattern observed when only the promoter was present (Supplemental Figure 2B ), suggesting that the enhancer region is dispensable for erlotinib and C. acnes-induced IL-36γ production in PHKs.
Therefore, and given the synergistic effect of erlotinib and C. acnes, this observation suggests that the IL-36γ promoter contains a binding site for an additional transcription factor to NF-κB p65. To identify this site, we generated IL-36γ reporters with promoter deletions of increasing lengths, thus mapping a genomic region located within 1130 and 1100 bp upstream of the first ATG as crucial for IL-36γ transcriptional activity ( Figure 2B -C). Furthermore, reporters containing mutations in either the genomic region located between 1130 and 1100 bp upstream of the first ATG or within the p65-binding site revealed, respectively, a 42% (p=0.010) and 81% (p=0.0003) reduction in IL-36γ transcriptional activity, whereas mutation of both regions resulted in a 92% (p=0.0002) reduction ( Figure 2D -E), indicating that both regions are required for optimal IL-36γ transcriptional activity.
To identify the putative transcription factor that binds to the -1130 to -1100 bp region of the IL-36γ gene promoter, we searched the JASPAR database, an open-access repository for matrix-based transcription factor binding profiles (37) , and identified fourteen transcription factors as potential candidates (Supplemental Figure 2C ). As no NF-κB-related transcription factors were revealed by this search, we hypothesized that the EGFRi-responsive site (EiRS) is located in this -1130 to -1100 bp region of the IL-36γ gene promoter. We subsequently performed quantitative PCR of mRNA derived from keratinocytes exposed to EGFR inhibitor erlotinib, and amongst these 14 candidates thereby identified a significant change in the expression levels of two transcription factors, KLF4 and ZEB1 ( Figure 2F ).
Since ZEB1 transcription decreased after EGFR inhibition, and is weakly expressed in normal keratinocytes (refs. 38, 39 and Supplemental Figure 2D ), we considered KLF4 as the probable candidate and assessed whether KLF4 could effectively bind to the EGFRi responsive region of the IL-36γ promoter. Using an electrophoretic mobility shift assay (EMSA), we could effectively demonstrate that KLF4 specifically binds to the DNA sequence within the -1130 to -1100 bp region of the IL-36γ gene promoter ( Figure 2G ). In line with the above, EGFR inhibition resulted in increased KLF4 expression in PHKs ( Figure 2H ), and DNA pull down assays performed with the same sequence as previously used in the EMSA revealed that KLF4 from erlotinib-exposed PHKs could specifically bind to the EGFR inhibitor-responsive region located between -1130 to -1100 bp upstream of the ATG in the IL-36γ gene promoter ( Figure 2I ). In addition, exposure of human skin ex vivo to erlotinib increased the expression of KLF4 ( Figure 2J ).
Lack of a KLF4 binding site in the mouse IL-36γ promoter precludes murine EGFRi-induced
IL-36γ response
Next, we examined IL-36γ production in response to EGFRi and NF-κB activation in primary murine keratinocytes (PMKs) . Surprisingly, despite the ability of the EGFR inhibitor erlotinib to block the phosphorylation of murine EGFR to a similar extent to that of human EGFR (Supplemental Figure 3A) , enhanced IL-36γ production was not observed, in contrast to the effect observed in human keratinocytes ( Figure 3A ). In this setting, PMKs were exposed to murine IL-36γ to achieve NF-κB activation given their weak response to C. acnes, Pam3CSK4 and lipopolysaccharide (LPS) (data not shown). In our culture conditions, PMKs already expressed high levels of KLF4 at the basal state (Supplemental Figure 3B ), a characteristic that was irrespective of the numerous culture conditions tested (data not shown). To test the requirement of KLF4 for IL-36γ transcription in mouse keratinocytes, we compared PMKs from KLF4-knockout mice and wild-type mice, and PMKs overexpressing KLF4, however, without being able to detect synergistic IL-36γ elevation after NF-κB activation as observed in human keratinocytes ( Figure 3B and Supplemental Figure 3C ). In accordance with the above, the putative KLF4 binding site identified by searching the JASPAR database, located at 1140 bp upstream of the first ATG in murine IL-36γ promoter ( Figure 3C ), could not be shown by EMSA to form a DNA-protein complex with mouse KLF4 ( Figure 3D ). Analysis of evolutionarily conserved regions in the genomes of sequenced species revealed that the KLF4 binding region in human IL-36γ promoter is conserved in the rhesus monkey and chimpanzee, but not in the mouse or rat, whereas the sequence of the IL-36γ promoter region corresponding to the p65 binding site is approximately 70% conserved in mice and rat as compared to humans (Supplemental Figure 3D and refs. 40, 41) . Alignment of the mouse and human IL-36γ gene loci revealed furthermore that the mouse genome lacks the region corresponding to the 583 bp long-region of human IL-36γ that contains the KLF4 binding site (-1120 bp) (Supplemental Figure 3E ). These results demonstrate that the mouse IL-36γ promoter is devoid of the KLF4 binding site found in humans, explaining the absence of synergistic induction of IL-36γ expression by EGFR inhibition and NF-κB activation in murine keratinocytes, and suggests that the mouse is not an appropriate model for the in vivo analysis of the acneiform skin toxicity to EGFRi.
Blockade of the EGFR-MEK-ERK pathway results in elevated KLF4 and IL-36γ expression
MEK inhibitors, which block the MAPK-ERK signaling pathway by inhibiting the MAP kinases MEK1 and MEK2, cause adverse skin reactions similar to those observed in EGFRitreated patients, including the commonly observed acneiform skin toxicity (4) . Quantitative PCR analysis of acneiform lesional skin biopsies from MEKi-treated patients revealed, as observed in EGFRi-treated patients, elevated IL-36γ (9.4-fold, p=0.0012) and IL-8 (15-fold, p=0.019), but not IL-1β or IL-6 mRNA levels ( Figure 4A and Supplemental Figure 4A ).
Since MEK is a downstream partner in the EGFR signaling pathway, we next assessed whether MEK inhibition could also result in elevated IL-36γ gene expression in PHKs. In vitro, the MEK inhibitors trametinib and selumetinib, together with C. acnes, synergistically induced elevated production of IL-36γ in PHKs, as previously observed with EGFRi ( Figure   4B left and Supplemental Figure 4B ). Similar results were observed upon ERK silencing with siRNA (Supplemental Figure 4C ). Of interest is the reported reduced incidence and severity of cutaneous skin toxicities observed in patients treated simultaneously with a BRAF inhibitor (BRAFi) and MEKi in clinical practice, as compared to patients treated with MEKi alone, and this has been shown to be due to paradoxical ERK activation in BRAF wild-type cells (42) (43) (44) . In line with this clinical observation, when PHKs were pre-exposed to the BRAFi vemurafenib prior to exposure to trametinib and C. acnes, the expression of IL-36γ mRNA induced by trametinib was significantly inhibited (7.4-fold, p=0.0002) ( Figure 4B Figure 4F ).
KLF4 enhances IL-36γ transcriptional activity upon EGFR/MEK inhibition
To determine if KLF4 is capable of enhancing IL-36γ transcriptional activity, we overexpressed KLF4 in PHKs. Such an overexpression resulted in enhanced IL-36γ expression at the protein level upon exposure of PHKs to C. acnes ( Figure 5A ). Similarly, doxycycline-inducible overexpression of wild-type KLF4 enhanced IL-36γ transcriptional activity whereas dominant-negative KLF4 mutant did not ( Figure 5B ). This demonstrates that forced expression of KLF4 can alone mimic the effect of EGFR/MEKi to drive IL-36γ production in keratinocytes. In accordance with this, siRNA silencing of KLF4 substantially suppressed the ability of EGFRi and C. acnes to enhance IL-36γ production ( Figure 5C ). The deletion of KLF4 in keratinocyte cell lines using the CRISPR/Cas9 system resulted in a loss of induction of IL-36γ gene expression in response to MEKi ( Figure 5D and Supplemental Figure 5A ). Furthermore, mutation of the KLF4-binding site in keratinocyte cell lines by CRISPR/Cas9 abrogated the ability of MEKi to induce IL-36γ transcription, whereas in these cell lines IL-1β expression was unaffected ( Figure 5E ). This demonstrates an essential role of KLF4 and its binding to the IL-36γ promoter in regulating IL-36γ transcriptional activity.
Consistent with a previous report (46) , inhibition of the EGFR-MEK-ERK pathway resulted in increased KLF4 expression in the nucleus of PHKs in vitro ( Figure 6A ). In acneiform skin lesions from EGFRi treated patients, abundant nuclear KLF4 expression could be observed in keratinocytes. In contrast, only low levels of nuclear KLF4 expression was observed in control skin samples ( Figure 6B -C). This data suggests that inhibition of either EGFR or MEK signaling enhances nuclear KLF4 expression in keratinocytes in the skin.
Discussion
Here we demonstrate that EGFR and MEK inhibitors partner with the commensal bacterium C. acnes that colonizes sebum rich skin to potently induce keratinocyte IL-36γ expression and drive IL-8-mediated neutrophil rich inflammation, the pathogenic hallmark of the so called "acneiform" skin toxicity frequently associated with these targeted agents. On the basis of in vitro and ex vivo investigations we pinpoint the regulation of keratinocyte IL-36γ expression upon EGFR blockade to two important signaling events. First, an upregulation of the expression and subsequent binding of the transcription factor KLF4 to its binding site in the promoter region of IL-36γ, and second, a signal provided by C. acnes resulting in the binding of NF-κB p65 to a sequence in close proximity to the above-mentioned KLF binding site.
Interestingly, the simultaneous binding of these two transcription factors to the IL-36γ As previously reported, the dysfunction of skin barrier and antimicrobial peptide production resulting from EGFR signaling abrogation are important events that can cause severe skin inflammation (13, 14) . It is unclear, however, to what extent this may contribute to the initiation of acneiform skin toxicity by EGFR/MEKi, possibly by facilitating the penetration of commensals such as C. acnes into the epidermis and/or pilo-sebaceous unit.
Indeed, a possible involvement of other stimuli in addition to EGFR inhibition are suggested in skin rash development of a mouse model (49) . KLF4 has been demonstrated to be a key driver of terminal epidermal differentiation in the skin (50) . The enhanced differentiation induced by increased KLF4 in response to EGFR/MEK inhibition might be an important event leading to the skin barrier dysfunction. KLF4 has only rarely been mentioned to be related to inflammatory diseases, but is known as a regulator of proinflammatory cytokine expression in rheumatoid arthritis (51) , and is one of the susceptibility genes for psoriasis (52, 53) , two diseases in which IL-36γ is significantly increased in the inflamed tissues (54) (55) (56) (57) .
Indeed, elevated expression of KLF4 has been reported in synovial tissue from rheumatoid arthritis patients and in the epidermis of psoriatic skin (51, 58) , but the exact role of KLF4 in the pathogenesis of these inflammatory diseases remains to be defined.
IL-36γ has been demonstrated to form a self-amplifying inflammatory loop in keratinocytes which express high levels of the IL-36 receptor (34, 59) . Besides DITRA, there is accumulating evidence that IL-36 signaling plays an important role in various neutrophilic dermatoses including generalized pustular psoriasis (GPP), palmo-plantar pustular psoriasis (PPP), acute generalized exanthematous pustulosis (AGEP) and acrodermatitis continua Hallopeau (60, 61) . The data presented here provides substantial evidence that acneiform skin toxicity caused by EGFR/MEKi should be added to the growing list of pustular skin diseases in which IL-36 likely plays a central pathogenic role. Our findings provide a basis for understanding the physiopathology of acneiform skin toxicity by caused EGFR/MEKi that may lead to better benefit from the antitumor effects with reduced side effects. Several IL-36 inhibitors have been developed and Phase 2 clinical trials of anti-IL-36 receptor antibody in patients with GPP and PPP are ongoing, suggesting that the latter may also offer a possibility for targeted therapy of acneiform skin toxicities by EGFR/MEKi in the near future.
Materials and Methods
Human skin samples: Biopsies were obtained from lesional skin of EGFR and MEK inhibitor-treated patients with acneiform eruption. Normal skin was obtained from specimens from the Plastic Surgery Department. All biopsies were immediately frozen in liquid nitrogen and stored at -80°C for RNA extraction or directly fixed in Formalin (4% (g/v)) for at least 24 hours for histology.
Mice: Klf4-floxed mice were obtained from MMRRC (Columbia, MO). Rosa26-CreER T2 mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Tamoxifen-inducible
Klf4 knockout mice were generated by crossing Rosa26-CreER T2 mice and Klf4-floxed mice.
Klf4 was knocked out by daily i.p. injection of tamoxifen at a dose of 100 mg/kg for five consecutive days. Wild-type C57BL/6 mice were obtained from Janvier labs (Le Genest-Saint-Isle, France).
Cell culture: Primary human keratinocytes were cultured as previously described (62) .
Briefly, primary human keratinocytes were isolated from fresh, surgically resected human neonatal foreskin. Keratinocytes were grown in keratinocyte serum free medium (#17005-042, Thermo Scientific, Waltham, MA), supplemented with EGF and BPE (Thermo Scientific) and seeded for experiments after 3 passages. All cells were maintained at 37 °C in a 5% CO2 humidified atmosphere. Primary mouse keratinocytes were isolated from pooled ear and tail. Briefly, skin specimens were incubated with the dermal side down at 37°C in The secondary antibodies used were alkaline phosphatase-conjugated mouse IgG (#S372B), rabbit IgG (#S373B) and goat IgG (#V115A) from Promega. Live C. acnes was prepared as previously described (63) . Table 2 ).
Gene expression array:
In situ hybridization: 620 nucleotide-long human IL-36γ cDNA was amplified using Pfu polymerase (Invitrogen) with primers (forward; 5'-ggaagctgctggagccacgattc-3', reverse; 5'aaagaccaagctgccacctctagg-3', excluding an additional flanking HindIII/EcoRI site) and cloned into pcDNA3 vector (Invitrogen). PCR fragments for probes were amplified with primers for CMV and BGH. The digoxigenin (DIG)-labeled antisense and sense RNA probes for human IL-36γ were synthesized by in vitro transcription using either SP6 or T7 RNA polymerase with the DIG RNA labeling kit (Roche). These probes were hydrolyzed in hydrolysis buffer (40mM NaHCO3, 60mM Na2CO3) to be 0.25 kb. The unincorporated nucleotides were removed using a spin column (Roche). Formalin-fixed paraffin-embedded tissue sections (4 μm) were deparaffinized and rehydrated in RNase-free condition. Sections were treated with 1 μg/ml proteinase K for 20 minutes and washed with 2xSSC for three times, followed by prehybridization for 2 h in 2xSSC containing 50 % formamide. Hybridization buffer (HB) contained 50% formamide, 4xSSC, 100 ng/ml yeast tRNA and 10% dextran sulfate. 25 ng DIG-labeled RNA probes were diluted in 50 μl HB, heated to 95 °C for 5 minutes, added to the tissues and hybridized overnight. After hybridization, the tissues were washed and incubated in stringent wash buffer (20% formamide, 2xSSC) at 42 °C for 30 minutes, followed by 2 μg/mL RNase A treatment at 37 °C for 1 hour. The sections were washed in 2xSSC and 0.2xSSC at 55°C each for 30 minutes and PBS at RT for 5 minutes. Blocking was performed in 5% BSA in PBS at RT for 1 h and sections were incubated in AP-conjugated anti-DIG Fab fragment (1/4000 dilution; Roche) at RT for 2 hours. After three washes in PBS for 5 minutes, tissues were stained using 2% NBT/BCIP in 0.1M NaCl, 0.1M Tris-HCl (pH 9) at RT in the dark for two days. 
ChIP-seq/DNase-seq/RNA-seq data analysis:
Raw sequencing data were converted to Fastq files by NCBI SRA Toolkit. Quality control on the raw data was performed by FastQC. The reads for ChIP-seq/DNase-seq were aligned to human reference genome (build GRCh37/hg19) by Bowtie2 Aligner. The mapped sequence reads were transformed to a binary format, sorted and indexed by SAMtools, followed by generation of coverage plots by BEDtools. These files were converted into BigWig files by BedGraphtoBigWig and visualized in IGV. ChIP-seq data from primary human keratinocytes were obtained from the following ChiP-seq/DNase-seq samples: GSM941735, GSM733698, GSM733674, GSM733636 and GSM816635. ChIP-seq data of p65 was from GSM935526. The reads for RNA-seq were aligned to human reference genome (build GRCh37/hg19) by HISAT2. The transcripts were assembled by Cufflinks, followed by generation of differential gene expression data by Cuffdiff. RNA-seq data from primary human keratinocytes were obtained from GSM2074746, GSM2074747 and GSM2074748. Table S3 ) were cloned into pLentiCRISPRv2 plasmid (Addgene, #98293). Samples for ubiquitin analysis were boiled at 95°C for 5 minutes in 1% SDS and sample buffer was added to dilute to 0.1% SDS. Samples were incubated overnight with anti-FLAG (1 μg) at 4 °C, followed by the addition of 30 μl protein A/G PLUS Agarose beads (Santa Cruz Biotechnology) and incubation for 2 hours. Immunoprecipitates were collected by centrifugation at 1,000 g for 5 minutes at 4 °C and the beads were then washed five times with lysis buffer. The beads were resuspended in 2x SDS sample buffer, boiled at 95 °C for 5 minutes and subjected to immunoblotting.
Luciferase reporter assay:
ELISA: Primary human keratinocytes were exposed to 1 μM erlotinib and 5 μg/mL Pam3CSK4 in 6-well plates for 48 hours. After washing three times with pre-warmed PBS, cells were incubated in fresh medium for 48 hours. After centrifugation, supernatants were collected and subjected to IL-36γ ELISA (Adipogen, Lausanne, Switzerland).
Ex vivo skin culture: Ex vivo skin culture was performed using a published protocol (65) with the following modifications. Full-thickness skin specimens were obtained from patients undergoing plastic or reconstructive surgery. Skin samples were cut to small pieces (4 x 4 mm) and placed in 24-well plates containing 0.5 ml of keratinocyte serum free medium (#17005-042, Thermo Scientific) supplemented with EGF, BPE (Thermo Scientific), 100 μg/mL kanamycin (Invitrogen) and 1.4 mM CaCl2 (Sigma-Aldrich). Tissue cultures were then incubated at 37 °C in a 5% CO2 atmosphere with fresh culture medium provided at 2 day intervals. Ex vivo skin explants were cultured with 1 μg/mL erlotinib for 24 hours for western blotting or for 4 days followed by snap freezing for subjecting to quantitative PCR. PHKs were exposed to erlotinib and C. acnes for 24 hours. (I) DNA pull-down assay using biotinylated wild-type-or mutant-oligonucleotide probe of the EiRS-containing region. These probes were incubated with extracts from PHKs exposed to erlotinib for 24 hours. DNAassociated proteins were visualized by western blotting. (J) Ex vivo skin explants from healthy controls were exposed to erlotinib for 24 hours and KLF4 expression was assessed by western blotting. The blot shown is representative of two different skin donors. Data were analyzed with 1-way ANOVA followed by Dunnett's multiple-comparisons test (A and E) or with 2-tailed unpaired Mann-Whitney U (C) or t test (F). *P<0.05, **P<0.01, ***P<0.001.
All blots were run contemporaneously with the same protein samples. knocked out keratinocyte cell lines by CRISPR/Cas9 were exposed to trametinib (2 μg/mL) for 24 hours and total cell lysates were collected for western blotting with antibodies to KLF4 and β-actin. The cells were exposed to trametinib for 24 hours and isolated RNA was subject 
